Brilliant Violet 605? anti-mouse/human CD44 Antibody
- 品名： Brilliant Violet 605? anti-mouse/human CD44 Antibody
- 型號： 103047
- 產品詳情
- 規格參數
Product Details
Isotype Control
Verified Reactivity
Mouse, Human
Reported Reactivity
Chimpanzee, Baboon, Cynomolgus, Rhesus, Squirrel Monkey, Horse, Cow, Pig, Dog, Cat
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Dexamethasone-induced myeloid leukemia M1 cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605? under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application
Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 μg per million cells in 100 μl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 605? excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605? is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet?.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.Excitation Laser
Violet Laser (405 nm)
Application Notes
Clone IM7 has been reported to recognize an epitope common to alloantigens and all isoforms of CD4417,18 that is located between amino acids 145 and 18620. This clone has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F). Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections6,7, complement-mediated cytotoxicity1, immunoprecipitation1,3, in vivo inhibition of DTH4,5, and spatial biology (IBEX)23,24. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 103046, 103065 - 103069).
Cross-reactivity to ferret has been reported by a collaborator, but not verified in house.Application References
(PubMed link indicates BioLegend citation)Trowbridge IS, et al. 1982. Immunogenetics 15:299. (ICFC, IP, CMCD)
Katoh S, et al. 1994. J. Immunol. 153:3440. (ELISA)
Budd RC, et al. 1987. J. Immunol. 138:3120. (IP)
Camp RL, et al. 1993. J. Exp. Med. 178:497. (Block)
Weiss JM, et al. 1997. J. Cell Biol. 137:1137. (Block)
Frank NY, et al. 2005. Cancer Res. 65:4320. (IHC) PubMed
Cuff CA, et al. 2001. J. Clin. Invest. 108:1031. (IHC)
Lee JW, et al. 2006. Nature Immunol. 8:181.
Zhang N, et al. 2005. J. Immunol. 174:6967. PubMed
Huabiao C, et al. 2005. J. Immunol. 175:591. PubMed
Gui J, et al. 2007. Int. Immunol. 19:1201. PubMed
Wang XY, et al. 2008. Blood 111:2436. PubMed
Product Citations
Fernandez HR, et al. 2018. Cell Death Differ. 25:1239. PubMed
Young JS, et al. 2018. Front Immunol. 9:1385. PubMed
Shi H et al. 2018. Immunity. 49(5):899-914 . PubMed
Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
Lercher A, et al. 2019. Immunity. 51:1074. PubMed
Leruste A, et al. 2020. Cancer Cell. 36(6):597-612.e8.. PubMed
McGinley AM, et al. 2020. Immunity. 52(2):342-356. PubMed
Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed
Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
Kim EH, et al. 2020. Elife. 9:00. PubMed
Dubois V, et al. 2021. NPJ Vaccines. 6:06. PubMed
Glassman CR, et al. 2021. eLife. 10:00. PubMed
RRID
AB_2562451 (BioLegend Cat. No. 103047)
